Version 1
: Received: 14 June 2023 / Approved: 15 June 2023 / Online: 15 June 2023 (11:35:43 CEST)
How to cite:
Photiades, A.; Vlassi, L.; Kontogianni, C.; Gaga, M.; Zervas, E. Tailored Therapy in Severe Asthma: The Importance of Moving beyond a Disease-Centric Approach. Preprints2023, 2023061133. https://doi.org/10.20944/preprints202306.1133.v1
Photiades, A.; Vlassi, L.; Kontogianni, C.; Gaga, M.; Zervas, E. Tailored Therapy in Severe Asthma: The Importance of Moving beyond a Disease-Centric Approach. Preprints 2023, 2023061133. https://doi.org/10.20944/preprints202306.1133.v1
Photiades, A.; Vlassi, L.; Kontogianni, C.; Gaga, M.; Zervas, E. Tailored Therapy in Severe Asthma: The Importance of Moving beyond a Disease-Centric Approach. Preprints2023, 2023061133. https://doi.org/10.20944/preprints202306.1133.v1
APA Style
Photiades, A., Vlassi, L., Kontogianni, C., Gaga, M., & Zervas, E. (2023). Tailored Therapy in Severe Asthma: The Importance of Moving beyond a Disease-Centric Approach. Preprints. https://doi.org/10.20944/preprints202306.1133.v1
Chicago/Turabian Style
Photiades, A., Mina Gaga and Eleftherios Zervas. 2023 "Tailored Therapy in Severe Asthma: The Importance of Moving beyond a Disease-Centric Approach" Preprints. https://doi.org/10.20944/preprints202306.1133.v1
Abstract
Despite recent advances in optimizing reliever, controller and maintenance therapy in asthma, a large subgroup of asthmatic patients continues to suffer from severe asthma, affecting their psychosociological status, their quality of life and even their life expectancy. Identifying and recognizing the specific phenotypic and endotypic characteristics in asthma has provided the medical community to drive the development of targeted therapies that are proved to benefit patients in terms of symptom control, exacerbation rate, quality of life and lung function. Adopting a more tailored and targeted approach is proving to be the key factor in reforming severe asthma treatment, minimizing the patients’ burden, as well as the socioeconomical impact worldwide. In this review, we are going to describe the different phenotypes and endotypes of asthma, the currently approved targeted therapies in severe asthma as imprinted in Global Initiative for Asthma (GINA) 2023, as well as other potential pharmacological agents and strategies investigated or currently under investigation for the treatment of severe asthma.
Keywords
severe asthma; phenotype; endotype; personalized medicine; targeted therapy; treatment
Subject
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
